INTEGER INVESTMENTS

- At the end of 2016, political claims sent pharma stocks into a tailspin. - We recommended starting positions and ABC and MCK performed well, while CAH lagged. - Today we re-analyze the three stocks. To read the full article click here. #TEGNA #TGNA #Stocks #stockmarket #Deere #IBM #Akorn #CVS #Nike

- Our portfolio performed very well in 2016 (26% ROC, 44.9% ROI) and we believe that we are well positioned for this year. - We are cautious on market risks and valuations. - We discuss our hedging strategy as well as our new investments. To read the full article click here. #TEGNA #TGNA #Stocks #stockmarket #Deere #IBM #Akorn #CVS #Nike

- Options’ strategies can reduce losses or create interesting income opportunities. - Considering current valuations, investors can protect their downside buying PUT options. - Investors can also sell CALL options that, in our opinion, are an interesting way to create value in a portfolio. - We recently sold CALL options in two of our holdings: GM and AKRX. To read the full article click here. #Options #Generalmotors #Akorn

- The pharma industry has been slammed by political campaigns. - Within the pharma industry, generic drug companies offer investing opportunities. - Akorn is a strong company that trades at conservative prices. To read the full article click here. #Pharmaceuticals #Akorn